Connect Biopharma Holdings (CNTB) Cash & Equivalents (2022 - 2026)
Connect Biopharma Holdings' Cash & Equivalents history spans 5 years, with the latest figure at $15.9 million for Q1 2026.
- On a quarterly basis, Cash & Equivalents fell 66.67% to $15.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.9 million, a 66.67% decrease, with the full-year FY2025 number at $38.3 million, up 1178.17% from a year prior.
- Cash & Equivalents hit $15.9 million in Q1 2026 for Connect Biopharma Holdings, down from $38.3 million in the prior quarter.
- Over the last five years, Cash & Equivalents for CNTB hit a ceiling of $161.9 million in Q4 2022 and a floor of $3.0 million in Q4 2024.
- Historically, Cash & Equivalents has averaged $64.3 million across 5 years, with a median of $44.2 million in 2025.
- Biggest five-year swings in Cash & Equivalents: crashed 97.16% in 2024 and later skyrocketed 1178.17% in 2025.
- Tracing CNTB's Cash & Equivalents over 5 years: stood at $161.9 million in 2022, then crashed by 34.72% to $105.7 million in 2023, then crashed by 97.16% to $3.0 million in 2024, then skyrocketed by 1178.17% to $38.3 million in 2025, then plummeted by 58.53% to $15.9 million in 2026.
- Business Quant data shows Cash & Equivalents for CNTB at $15.9 million in Q1 2026, $38.3 million in Q4 2025, and $37.8 million in Q3 2025.